Cancer Causes & Control

, Volume 21, Issue 3, pp 463–472 | Cite as

Blood pressure and risk of prostate cancer: cohort Norway (CONOR)

  • Richard M. Martin
  • Lars Vatten
  • David Gunnell
  • Pål Romundstad
Original paper

Abstract

Background

Some studies suggest that raised blood pressure may increase prostate cancer risk. We investigated associations of blood pressure with prostate cancer within the CONOR collaborative cohorts of Norway.

Methods

Between 1994 and 2003, 82,098 men from ten population-based cohorts in Norway completed standardised questionnaires and physical examinations, including resting blood pressure. The unique 11-digit identification number of Norwegian citizens allowed linkage with the Cancer Registry of Norway.

Results

A total of 78,768 (96%) men who were cancer-free at baseline and average age of 50.3 years (standard deviation, SD: 15.2) were followed up for a mean of 9.15 years. 11.4% of these men used antihypertensive drugs at baseline. During follow-up (1994–2006), 1,974 incident prostate cancers were diagnosed. We found a 4% (95% confidence interval, CI = 0–9%) increased risk of prostate cancer per one SD (18.3 mmHg) increase in systolic blood pressure and similar findings for diastolic blood pressure (hazard ratio, HR: 1.05 per SD; 95% CI = 1.01–1.10). The association was stronger for advanced (HR: 1.16 per SD increase in systolic blood pressure; 95% CI = 1.05–1.27) compared with localised (1.01; 0.95–1.08) prostate cancer (p for heterogeneity in hazard ratios = 0.02).

Conclusions

Raised blood pressure was associated with an increased risk of prostate cancer, particularly advanced cancers at diagnosis. Understanding the mechanisms underlying these findings may provide biological insights into prostate carcinogenesis. Even if the association was causal, our data suggest that raised blood pressure would account for only 3% of prostate cancers, so the public health impact of this association may be limited.

Keywords

Prostate cancer Blood pressure Anti-hypertensives Prostate cancer mortality 

Supplementary material

10552_2009_9477_MOESM1_ESM.doc (78 kb)
(DOC 78 kb)

References

  1. 1.
    Parkin DM (2004) International variation. Oncogene 23(38):6329–6340CrossRefPubMedGoogle Scholar
  2. 2.
    Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23(1):3–13PubMedGoogle Scholar
  3. 3.
    Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F et al (2008) Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 123:421–429CrossRefPubMedGoogle Scholar
  4. 4.
    Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU International 90:162–173CrossRefPubMedGoogle Scholar
  5. 5.
    Yatani R, Shiraishi T, Nakakuki K, Kusano I, Takanari H, Hayashi T et al (1988) Trends in frequency of latent prostate carcinoma in Japan from 1965–1979 to 1982–1986. J Natl Cancer Inst 80(9):683–687CrossRefPubMedGoogle Scholar
  6. 6.
    Peto J (2001) Cancer epidemiology in the last century and the next decade. Nature 411(6835):390–395CrossRefPubMedGoogle Scholar
  7. 7.
    Yu H, Harris RE, Gao YT, Gao R, Wynder EL (1991) Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol 20(1):76–81CrossRefPubMedGoogle Scholar
  8. 8.
    Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R et al (2008) Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol 37(1):147–160CrossRefPubMedGoogle Scholar
  9. 9.
    Reddy KS, Yusuf S (1998) Emerging epidemic of cardiovascular disease in developing countries. Circulation 97(6):596–601PubMedGoogle Scholar
  10. 10.
    Giovannucci E (2003) Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 35(11/12):694–704CrossRefPubMedGoogle Scholar
  11. 11.
    Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH (2002) Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 3(4):303–308CrossRefPubMedGoogle Scholar
  12. 12.
    Lawes CM, Hoorn SV, Rodgers A (2008) Global burden of blood-pressure-related disease, 2001. Lancet 371(9623):1513–1518CrossRefPubMedGoogle Scholar
  13. 13.
    Dyer A, Berkson D, Stamler J, Lindberg H, Stevens E (1975) High blood pressure: a risk factor for cancer mortality? Lancet 305(7915):1051–1056CrossRefGoogle Scholar
  14. 14.
    Grossman E, Messerli FH, Boyko V, Goldbourt U (2002) Is there an association between hypertension and cancer mortality? Am J Med 112(6):479–486CrossRefPubMedGoogle Scholar
  15. 15.
    Hamet P (1996) Cancer and hypertension: an unresolved issue. Hypertension 28(3):321–324PubMedGoogle Scholar
  16. 16.
    Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA (2007) Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 109(5):875–881CrossRefPubMedGoogle Scholar
  17. 17.
    Martin R, Vatten L, Gunnell D, Romundstad P, Nilsen T (2009) Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. doi: 10.1007/s10552-009-9319-x
  18. 18.
    Davis MJ, Lane JA, Gilbert R, Martin R, Donovan JL, Neal DE et al (2008) Raised blood pressure predicts prostate cancer and elevated PSA in a large unselected population of men participating in the ProtecT study. Eur Urol Suppl 7(3):198CrossRefGoogle Scholar
  19. 19.
    Hammarsten J, Hogstedt B (2004) Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13(1):47–55CrossRefPubMedGoogle Scholar
  20. 20.
    Friedman GD (1997) Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol 7(7):486–489CrossRefPubMedGoogle Scholar
  21. 21.
    Gann PH, Daviglus ML, Dyer AR, Stamler J (1995) Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 4(6):611–616PubMedGoogle Scholar
  22. 22.
    Platz EA (2007) Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev 16(11):2175–2180CrossRefPubMedGoogle Scholar
  23. 23.
    Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (2001) Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11(8):534–542CrossRefPubMedGoogle Scholar
  24. 24.
    Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4):833–843CrossRefPubMedGoogle Scholar
  25. 25.
    Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C et al (2008) Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci USA 105(24):8369–8374CrossRefPubMedGoogle Scholar
  26. 26.
    Naess O, Sogaard AJ, Arnesen E, Beckstrom AC, Bjertness E, Engeland A et al (2008) Cohort profile: cohort of Norway (CONOR). Int J Epidemiol 37(3):481–485CrossRefPubMedGoogle Scholar
  27. 27.
    Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B et al (2007) Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 99(24):1881–1887CrossRefPubMedGoogle Scholar
  28. 28.
    Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121(7):1571–1578CrossRefPubMedGoogle Scholar
  29. 29.
    Kom EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145(1):72–80Google Scholar
  30. 30.
    Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M et al (2008) Height and prostate cancer risk: a large nested case–control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 17(9):2325–2336CrossRefPubMedGoogle Scholar
  31. 31.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348(17):1625–1638CrossRefPubMedGoogle Scholar
  32. 32.
    Nilsen TI, Romundstad PR, Vatten LJ (2006) Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer 119(12):2943–2947CrossRefPubMedGoogle Scholar
  33. 33.
    Freeman MR, Solomon KR (2004) Cholesterol and prostate cancer. J Cell Biochem 91(1):54–69CrossRefPubMedGoogle Scholar
  34. 34.
    Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al (2004) British hypertension society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328(7440):634–640CrossRefPubMedGoogle Scholar
  35. 35.
    Kirkwood BR, Sterne JAC (2003) Essential medical statistics, 2nd edn. Blackwell Science, OxfordGoogle Scholar
  36. 36.
    Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD (1996) Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 30(2):138–144PubMedGoogle Scholar
  37. 37.
    Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B et al (1977) Latent carcinoma of prostate at autopsy in seven areas. The international agency for research on cancer, Lyons, France. Int J Cancer 20(5):680–688CrossRefPubMedGoogle Scholar
  38. 38.
    Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A et al (2004) Natural history of early, localized prostate cancer. JAMA 291(22):2713–2719CrossRefPubMedGoogle Scholar
  39. 39.
    Harvei S, Tretli S, Langmark F (1996) Quality of prostate cancer data in the cancer registry of Norway. Eur J Cancer 32(1):104–110CrossRefGoogle Scholar
  40. 40.
    Albertsen PC, Hanley JA, Fine J (2005) 20-Year outcomes following conservative management of clinically localized prostate cancer. J Am Med Assoc 293(17):2095–2101CrossRefGoogle Scholar
  41. 41.
    McCarty MF (1997) Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. Med Hypotheses 48(4):297–308CrossRefPubMedGoogle Scholar
  42. 42.
    Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429CrossRefPubMedGoogle Scholar
  43. 43.
    Chen R, Tunstall-Pedoe H (2002) Cancer risk, hypertension, and antihypertensive medication. Lancet 359(9300):77CrossRefPubMedGoogle Scholar
  44. 44.
    Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352(9123):179–184CrossRefPubMedGoogle Scholar
  45. 45.
    Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B et al (2001) Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358(9281):539–544CrossRefPubMedGoogle Scholar
  46. 46.
    Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JW, Gillis CR et al (1993) Incidence of and mortality from cancer in hypertensive patients. BMJ 306(6878):609–611CrossRefPubMedGoogle Scholar
  47. 47.
    Rodriguez C, Jacobs E, Deka A, Patel A, Bain E, Thun M et al (2009) Use of blood-pressure-lowering medication and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Causes Control 20(5):671–679CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Richard M. Martin
    • 1
  • Lars Vatten
    • 1
    • 2
  • David Gunnell
    • 1
  • Pål Romundstad
    • 2
  1. 1.Department of Social MedicineUniversity of BristolBristolUK
  2. 2.Department of Public HealthNorwegian University of Science and TechnologyTrondheimNorway

Personalised recommendations